【制药网 企业新闻】6月24日盘后,康哲药业发布公告称,建议将其普通股(股份)以介绍方式于新加坡证券交易所有限公司(新交所)作第二上市。建议第二上市(倘落实进行)将不涉及增发新股,其后股份将继续于港交所作主要上市及买卖。据公告,康哲药业已按保密基准向新交所递交建议第二上市的上市申请。截至本次公告日,公司尚未从新交所接获建议第二上市的上市资格函。2025年6月24日,公司获得中国证监会就建议第二上市...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.